251 related articles for article (PubMed ID: 30562858)
61. Orchestrating immune check-point blockade for cancer immunotherapy in combinations.
Perez-Gracia JL; Labiano S; Rodriguez-Ruiz ME; Sanmamed MF; Melero I
Curr Opin Immunol; 2014 Apr; 27():89-97. PubMed ID: 24485523
[TBL] [Abstract][Full Text] [Related]
62. Immune checkpoint inhibition in lymphoid disease.
Eyre TA; Collins GP
Br J Haematol; 2015 Aug; 170(3):291-304. PubMed ID: 25824455
[TBL] [Abstract][Full Text] [Related]
63. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches.
Spigel DR; Socinski MA
J Thorac Oncol; 2013 May; 8(5):587-98. PubMed ID: 23546044
[TBL] [Abstract][Full Text] [Related]
64. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
65. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
[TBL] [Abstract][Full Text] [Related]
66. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
[TBL] [Abstract][Full Text] [Related]
67. Recent developments and future challenges in immune checkpoint inhibitory cancer treatment.
Koster BD; de Gruijl TD; van den Eertwegh AJ
Curr Opin Oncol; 2015 Nov; 27(6):482-8. PubMed ID: 26352539
[TBL] [Abstract][Full Text] [Related]
68. Immunotherapy in advanced gastric cancer, is it the future?
Coutzac C; Pernot S; Chaput N; Zaanan A
Crit Rev Oncol Hematol; 2019 Jan; 133():25-32. PubMed ID: 30661655
[TBL] [Abstract][Full Text] [Related]
69. [Immune-related adverse events of immune checkpoint inhibitors].
Tadano H; Torigoe T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):102-108. PubMed ID: 28603200
[TBL] [Abstract][Full Text] [Related]
70. [The "immune checkpoints", how does it work].
Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H
Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999
[TBL] [Abstract][Full Text] [Related]
71. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
[TBL] [Abstract][Full Text] [Related]
72. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
73. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
74. Immune checkpoint blockade therapy: the 2014 Tang Prize in Biopharmaceutical Science.
Chen YS; Shen CR
Biomed J; 2015; 38(1):5-8. PubMed ID: 25673064
[TBL] [Abstract][Full Text] [Related]
75. Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
Liu YL; Zamarin D
Curr Oncol Rep; 2018 Nov; 20(12):94. PubMed ID: 30421009
[TBL] [Abstract][Full Text] [Related]
76. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
77. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
78. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
[TBL] [Abstract][Full Text] [Related]
79. Evaluation of immunotherapy efficacy in gynecologic cancer.
Jiang G; Wu Q; Li B
Front Immunol; 2023; 14():1061761. PubMed ID: 36793735
[TBL] [Abstract][Full Text] [Related]
80. Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?
Taha T; Reiss A; Amit A; Perets R
BioDrugs; 2020 Dec; 34(6):749-762. PubMed ID: 33141420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
